Skip to content

Ketamine: all studies

Page 208 of 449: studies 2,071 to 2,080 of 4,486, newest first. Back to the ketamine overview

Research

KETAMINE THERAPY COMBINED WITH REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (rTMS) FOR MAJOR DEPRESSIVE DISORDER AT A SUBURBAN TERTIARY CLINIC

Brain Stimulation September 1, 2021 M. Davila, A. Hess, Ananya Louviere et al.

Background: Repetitive transcranial magnetic stimulation (rTMS) is a neurostimulatory technique approved for the treatment of major https://doi.org/10.1016/j.brs.2021.07.023 depressive disorder (MDD) impacting orbital frontal cortex functioning. We have previously identified significant changes in ratings for several standard metrics for depression, anxiety, pain and ADHD after 6 weeks of...

Ketamine-Assisted and Culturally Attuned Trauma Informed Psychotherapy as Adjunct to Traditional Indigenous Healing: Effecting Cultural Collaboration in Canadian Mental Health Care.

Behavioral Sciences August 31, 2021 Sherry-Anne Muscat, Geralyn Dorothy Wright, Kristy Bergeron et al. 5 citations

Ketamine therapy with culturally attuned trauma-informed psychotherapy in a collaborative cross-cultural partnership may provide a critical step in the operationalization and optimization of treatment effectiveness in diverse populations and may provide a foundation for an improved quality of life for Indigenous people. Decolonizing Indigenous health and wellbeing is long overdue, requiring an...

Low Doses of Ketamine and Melatonin in Combination Produce Additive Antidepressant-like Effects in Mice

International Journal of Molecular Sciences August 26, 2021 Rosa Estrada-Reyes, Daniel B Quero-Chávez, Citlali Trueta et al.

Major depressive disorder is a disabling disease with the number of affected individuals increasing each year. Current antidepressant treatments take between three to six weeks to be effective with forty percent of patients being resistant to treatment, making it necessary to search for new antidepressant treatments. Ketamine, a phencyclidine hydrochloride derivative, given intravenously,...

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review

Cureus August 21, 2021 Alisha Sapkota, Hajra Khurshid, Israa A Qureshi et al. 44 citations

Intranasal form of esketamine, the S-enantiomer of racemic ketamine, was approved by the US FDA in 2019 for treatment-resistant depression (TRD) in adults. Since intranasal esketamine is a newly approved drug with a novel mechanism of action, much still remains unknown in regard to its use in TRD. The objective of this study is to systematically review the latest existing evidence on intranasal...

A hidden Markov model reliably characterizes ketamine-induced spectral dynamics in macaque local field potentials and human electroencephalograms

PLoS Computational Biology August 18, 2021 Sourish Chakravarty, Indie C. Garwood, S. Chakravarty et al. 32 citations

Ketamine is an NMDA receptor antagonist commonly used to maintain general anesthesia. At anesthetic doses, ketamine causes high power gamma (25-50 Hz) oscillations alternating with slow-delta (0.1-4 Hz) oscillations. These dynamics are readily observed in local field potentials (LFPs) of non-human primates (NHPs) and electroencephalogram (EEG) recordings from human subjects. However, a detailed...

DOI: 10.1371/journal.pcbi.1009280 (opens in new tab) Full text (opens in new tab) Ketamine Local field potential Hidden markov model Electroencephalography +5

Structural connectivity and subcellular changes after antidepressant doses of ketamine and Ro 25-6981 in the rat: an MRI and immuno-labeling study

Brain Structure and Function August 7, 2021 Raquel Pascual-Antón, Arantxa Blasco‐Serra, Emma Muñoz‐Moreno et al. 6 citations

Ketamine has rapid and robust antidepressant effects. However, unwanted psychotomimetic effects limit its widespread use. Hence, several studies examined whether GluN2B-subunit selective NMDA antagonists would exhibit a better therapeutic profile. Although preclinical work has revealed some of the mechanisms of action of ketamine at cellular and molecular levels, the impact on brain circuitry...

Efficacy of Oral Ketamine Combined with Psychotherapy for Treatment Resistant Depression

European Journal of Medical and Health Sciences August 5, 2021 Tatiana Zydb, Michael Hart 4 citations

Background: Treatment resistant depression (TRD) is defined as a major depressive episode that does not improve in response to at least two trials, each of a different class, of antidepressant medication. Pharmacotherapy of TRD with low dose ketamines has been shown as relatively successful in recent studies. Effects of such pharmacotherapy can be augmented by combining ketamine with...

Ready for a "breakthrough" with ketamine? A look at recent pharmacological insights!

Current Opinion in Anaesthesiology August 1, 2021 Sabine Himmelseher, Eberhard F Kochs

To update pharmacological insights on ketamine integrating information from different disciplines for developing steps to "breakthrough" approaches in clinical challenges. Pharmacokinetic/pharmacodynamic (PK/PD) models have incorporated recirculation, ketamine metabolites, drug-drug interaction, and covariates such as age. Ketamine-induced relief from treatment-resistant depression has been...

Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression

CNS Spectrums August 1, 2021 Mu-Hong Chen, Wei-Chen Lin, Hui-Ju Wu et al.

AbstractBackgroundThe antidepressant effect of low-dose ketamine infusion on Taiwanese patients with anxious vs nonanxious treatment-resistant depression (ANX-TRD vs NANX-TRD) has remained unknown.MethodsIn total, 71 patients with TRD were randomized to three groups. Each group had participants who received saline infusions mixed with 0 (a normal saline infusion), 0.2, and 0.5 mg/kg of...

Rapid-acting antidepressants and the regulation of TrkB neurotrophic signalling-Insights from ketamine, nitrous oxide, seizures and anaesthesia.

Basic & Clinical Pharmacology & Toxicology August 1, 2021 Samuel Kohtala, Tomi Rantamäki

Increased glutamatergic neurotransmission and synaptic plasticity in the prefrontal cortex have been associated with the rapid antidepressant effects of ketamine. Activation of BDNF (brain-derived neurotrophic factor) receptor TrkB is considered a key molecular event for antidepressant-induced functional and structural synaptic plasticity. Several mechanisms have been proposed to underlie...

DOI: 10.1111/bcpt.13598 (opens in new tab) Full text (opens in new tab) Electroencephalogram Energy metabolism Protein phosphorylation Rapid-acting antidepressant +1